Immunology Drugmaker Electra Seeks to Raise $347 Million in IPO

Electra Therapeutics, a clinical-stage immunology drug developer, is seeking to raise up to $347 million through a US initial public offering. The proposed listing signals continued access to public-equity funding for pre-revenue biotechnology companies, though the company’s valuation, pricing and timing were not disclosed.